CurrentPartnering is a publisher of business development best practice and deal terms reports
A list of our latest reports is provided below or view a full list of CurrentPartnering reports.
JUST PUBLISHED: Partnering Agreements with....
Abbott, Actavis, Alcon, Allergan, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Cephalon, Chugai, CSL, Daiichi Sankyo, Dainippon Sumitomo, Eisai, Eli Lilly, Forest, Genentech, Genzyme, Gilead, GlaxoSmithKline, Hospira, Johnson & Johnson, Lundbeck, Menarini, Merck & Co, Merck Serono, Mitsubishi Tanabe, Mylan, Novartis, Novo Nordisk, Nycomed, Otsuka, Prizer, Ratiopharm, Roche, Sanofi-Aventis, Servier, Shire, Solvay, Takeda, Teva, UCB, Watson.
Providing detailed understanding and analysis of bigpharma companies entering partnering deals, including access to actual contract agreements
NEW REPORT: Drug Delivery Partnering Agreements in Pharma and Biotech
Providing detailed understanding and analysis of how and why companies enter drug delivery partnering deals, plus access to actual contract agreements find out more now
NEW REPORT: Partnering Agreements in Diagnostics
Providing detailed understanding and analysis of how and why companies enter diagnostic partnering deals, plus access to actual diagnostic agreements find out more now here
NEW REPORT: Oncology Partnering Agreements in Pharma, Biotech and Diagnostics
Providing detailed understanding and analysis of how and why companies enter oncology partnering deals, plus access to actual oncology agreements order here now
REVISED AND UPDATED: Manufacturing and Supply Agreements in Pharma, Biotech and Diagnostics
Provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the worlds leading biopharma companies order here today
NEW REPORT: Option & Evaluation Agreements in Pharma and Biotech
Providing detailed understanding and analysis of how and why companies enter option and evaluation deals, plus access to actual option and evaluation agreements order now here
NEW REPORT: Royalty Financing Agreements in Pharma, Biotech and Diagnostics
Providing detailed understanding and analysis of how and why companies enter royalty financing deals, plus access to actual royalty financing agreements order here
OTHER RECENT REPORTS
Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics, 2nd edition
Providing detailed understanding and analysis of how and why companies enter co-promotion and co-marketing deals, plus access to actual agreements Co-promotion and Co-marketing Agreements in Biopharma
Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics, 2nd edition
Providing detailed understanding and analysis of how and why companies enter M&A deals, plus access to actual M&A agreements Merger and Acquisition Agreements in Biopharma
Product and Asset Purchase Agreements in Pharm, Biotech & Diagnostics
Providing detailed understanding and analysis of how and why companies enter asset purchase deals, plus 100s of asset purchase agreements order now
Other reports from CurrentPartnering
Plus 100s of other reports and books on partnering best practice available and updated weekly Browse reports
IN THE NEWS
In the news: Partnering continues to gain momentum into 2010
Recent deals include Starpharma and Eli Lilly sign new drug delivery collaboration; Cephalon to buy generic firm Mepha for $590 million; Amgen and Stiefel in Enbrel promotion pact; Imperial Innovations licences meningjitis B vaccine to Novartis - more news
NETWORKS NOW INCLUDES LINKEDIN DISCUSSION GROUPS
CurrentPartnering's LinkedIn group now includes active discussion and news streams.
CurrentPartnering Networks - a series of online social network groups for the biopharma dealmaker - includes LinkedIn, Plaxo, Facebook, Twitter...
ARTICLES
Royalty Rates For Technology Transactions
An interesting study was carried out between 1990 and 2007 which discovered that the most frequently negotiated royalty rate is 5% of net sales - read now
Big Pharma seeks to insulate itself from impact of ‘patent cliff’
As the pharmaceutical industry hurtles ever closer towards the ‘patent cliff’, Big Pharma* is busy implementing strategies to lessen the impact of the loss of patent protection on some of the industry’s biggest sellers on their collective bottom lines more on this article
EVENTS
Partnering events for winter 2010
Next up: 10th MedTech Investing Europe Conference; BIO-Windhover 2010; Pharmaceutical Strategic Outlook 2010; BioNetwork East 2010; EuroPLX 42 Valletta more events
PEOPLE
People on the move
Updated daily to provide the latest on career moves during winter 2010 career updates
RESOURCES
The best of the web for dealmakers
The best partnering resources available online - from software tools to partnering quotes to reference library View resources
SCORECARD
The highest value partnering and M&A deals of 2009 more scorecards
Scorecard Index
Deal term reports
The information you provide is excellent and we look forward to doing more business with you in the future
...You have published very timely and interesting materials.... I am excited.... It is an excellent publication and pretty well up to date...
CurrentPartnering Reports
The latest reports on best practise for dealmakers available from CurrentPartnering
Quick links
Term of the week...
Supplementary Protection Certificate (SPC) - granted to extend the period of protection under a patent in respect of a specified pharmaceutical (or plant protection) product that is protected by the patent